Immuneering (IMRX) Invested Capital: 2020-2024
Historic Invested Capital for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $57.7 million.
- Immuneering's Invested Capital fell 44.51% to $57.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $57.7 million, marking a year-over-year decrease of 44.51%. This contributed to the annual value of $90.6 million for FY2023, which is 17.55% down from last year.
- Immuneering's Invested Capital amounted to $57.7 million in Q3 2024, which was down 12.95% from $66.3 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Invested Capital registered a high of $158.3 million during Q3 2021, and its lowest value of -$35.2 million during Q2 2021.
- In the last 3 years, Immuneering's Invested Capital had a median value of $104.0 million in 2023 and averaged $101.8 million.
- In the last 5 years, Immuneering's Invested Capital spiked by 793.82% in 2021 and then tumbled by 44.51% in 2024.
- Quarterly analysis of 5 years shows Immuneering's Invested Capital stood at -$22.5 million in 2020, then soared by 793.82% to $156.0 million in 2021, then fell by 29.57% to $109.9 million in 2022, then dropped by 17.55% to $90.6 million in 2023, then slumped by 44.51% to $57.7 million in 2024.
- Its Invested Capital was $57.7 million in Q3 2024, compared to $66.3 million in Q2 2024 and $78.7 million in Q1 2024.